Oral C-Met Inhibitor MSC2156119J as Monotherapy Versus Sorafenib in First-Line Treatment of Asian Patients with Met-Positive Advanced Hepatocellular Carcinoma and Child-Pugh Class a Liver Function: Phase IB/II, Multicenter, Randomized Trial

Authors :: Qin Shukui
Cheng Ann-Lii
Li Cindy
Massimini Giorgio
Lim Ho Yeong
Xu Lianzhe
Source :: Annals of Oncology. 25:ii45
Publication Year :: 2014
Publisher :: Elsevier BV, 2014.

Subjects :: Oncology
Sorafenib
medicine.medical_specialty
C-Met Inhibitor MSC2156119J
business.industry
Hematology
medicine.disease
law.invention
First line treatment
Randomized controlled trial
law
Internal medicine
Hepatocellular carcinoma
Medicine
Liver function
business
MET Positive
medicine.drug

Full Text Access

Tools